文献速递眼底病与葡萄膜炎

玻璃体腔联合阿柏西普与抗PDGFRβ治疗新生血管性年龄相关性黄斑变性:2期CAPELLA试验结果

Intravitreal Combined Aflibercept + Anti-Platelet-Derived Growth Factor Receptor β for Neovascular Age-Related Macular Degeneration: Results of the Phase 2 CAPELLA Trial.
PubMed 文献 · Ophthalmology · 2019-09-25

CAPELLA为2期随机双盲研究,纳入505眼治疗初治新生血管性年龄相关性黄斑变性,比较阿柏西普联合抗PDGFRβ与阿柏西普单药。第12周联合组BCVA获益未优于单药组,单药组完全积液消退比例更高;高剂量联合组眼内炎症发生率较高。

要点

  • 联合抗PDGFRβ未在12周BCVA上优于阿柏西普单药。
  • 单药组完全积液消退比例42%,高于低剂量联合35%和高剂量联合24%。
  • 高剂量联合组眼内炎症发生率7.5%,需关注安全性。

核心结论

  • 玻璃体腔阿柏西普联合抗PDGFRβ未较阿柏西普单药改善BCVA。
  • 评估完全积液消退的解剖学结局 favoring 阿柏西普单药。
  • 不良事件总体与阿柏西普已知安全性一致,但高剂量联合组眼内炎症更常见。

研究设计与样本

  • 2期随机双盲研究,共505例(眼)治疗初治新生血管性年龄相关性黄斑变性患者。
  • 按1:2:2随机分为低剂量联合组(抗PDGFRβ 1 mg+阿柏西普2 mg)、高剂量联合组(抗PDGFRβ 3 mg+阿柏西普2 mg)和阿柏西普单药组,每4周给药至第12周。
  • 第12周高剂量联合组和单药组再随机分为继续原方案或互换方案,每4周给药至第28周;第28至52周按预设标准按需治疗。
  • 主要终点为第12周BCVA较基线平均变化;报告第28周疗效和第52周安全性。

主要发现

  • 第12周BCVA较基线平均增益:低剂量联合组5.8字母、高剂量联合组5.8字母、单药组7.5字母(低剂量联合 vs 单药P=0.21;高剂量联合 vs 单药P=0.10)。
  • 第12周BCVA增益≥15字母比例:低剂量联合组12%、高剂量联合组19%、单药组22%。
  • 第12周黄斑中心视网膜厚度较基线平均降低:低剂量联合组126.1 μm、高剂量联合组127.1 μm、单药组126.9 μm。
  • 第12周完全积液消退比例:低剂量联合组35%、高剂量联合组24%、单药组42%。
  • 第28周视力和解剖学结局与第12周结果一致。

关键数值与推荐

  • 第52周眼内炎症发生率分别为1.0%、7.5%、2.1%、2.1%和0%(对应分组原文未逐项标注)。
  • 第52周抗血小板试验协作组定义动脉血栓栓塞事件发生率分别为1.9%、0.9%、1.1%、2.1%和1.9%(对应分组原文未逐项标注)。

临床怎么用

  • 对于治疗初治新生血管性年龄相关性黄斑变性,阿柏西普联合抗PDGFRβ未显示优于阿柏西普单药的视力获益。
  • 高剂量联合方案与更高的眼内炎症发生率相关,临床选择联合方案时需权衡安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare the efficacy and safety of intravitreal aflibercept + anti-platelet-derived growth factor receptor β (PDGFRβ) combination with intravitreal aflibercept injection (IAI) monotherapy in patients with treatment-naïve neovascular age-related macular degeneration (nAMD). DESIGN: Phase 2, randomized, double-masked study. PARTICIPANTS: A total of 505 patients (eyes) with nAMD. METHODS: Patients were randomized 1:2:2 to low-dose combination intravitreal anti-PDGFRβ 1 mg and aflibercept 2 mg (LD combo), high-dose combination intravitreal anti-PDGFRβ 3 mg and aflibercept 2 mg (HD combo), or IAI alone every 4 weeks through week 12. At week 12, patients in the HD combo and IAI groups were re-randomized to continue as assigned or switch to HD combo → IAI or IAI → HD combo and dosed every 4 weeks through week 28. During weeks 28 to 52, patients received treatment as needed per prespecified criteria. This report presents efficacy through week 28 and safety through week 52. MAIN OUTCOME MEASURES: Mean best-corrected visual acuity (BCVA) change from baseline at week 12 (primary end point). RESULTS: At week 12, mean BCVA gains from baseline were 5.8, 5.8, and 7.5 letters with LD combo, HD combo, and IAI, respectively (P = 0.21 for LD combo and P = 0.10 for HD combo vs. IAI). The corresponding proportions of eyes that gained ≥15 letters were 12%, 19%, and 22%, respectively. Mean reductions in central retinal thickness from baseline were 126.1, 127.1, and 126.9 μm, respectively. Proportions of eyes with complete resolution of fluid from baseline were 35%, 24%, and 42%, respectively. Vision and anatomic outcomes at week 28 were consistent with the week 12 results. Through week 52, the incidence of intraocular inflammation was 1.0%, 7.5%, 2.1%, 2.1%, and 0%, respectively. The incidence of Anti-Platelet Trialists' Collaboration-defined arterial thromboembolic events was 1.9%, 0.9%, 1.1%, 2.1%, and 1.9%, respectively. CONCLUSIONS: Intravitreal aflibercept + anti-PDGFRβ did not improve BCVA over IAI alone. Anatomic outcomes evaluating complete fluid resolution favored IAI. Adverse events were consistent with the reported IAI safety profile, except for a higher frequency of intraocular inflammation in the HD combo group.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Heier JS, Wykoff CC, Waheed NK, et al. Intravitreal Combined Aflibercept + Anti-Platelet-Derived Growth Factor Receptor β for Neovascular Age-Related Macular Degeneration: Results of the Phase 2 CAPELLA Trial. Ophthalmology. 2019. PMID: 31791663. doi:10.1016/j.ophtha.2019.09.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。